France’s Servier Acquires Potential Fragile X Drug In $450 Million Deal

Les Laboratoires Servier is acquiring a potential treatment for Fragile X syndrome for as much as $450 million, another step to expand the French drugmaker’s development focus beyond cancer into neurology....

Redirecting to full article...